Alexandra Nikolaeva, Maria Pospelova, Varvara Krasnikova, Albina Makhanova, Samvel Tonyan, Yurii Krasnopeev, Evgeniya Kayumova, Elena Vasilieva, Aleksandr Efimtsev, Anatoliy Levchuk, Gennadiy Trufanov, Mark Voynov, Maxim Shevtsov
Vestibulo-atactic syndrome (VAS), which represents a combination of motor and vestibular disorders, can be manifested as a clinical complication of breast cancer treatment and has a significant impact on patients' quality of life. The identification of novel potential biomarkers that might help to predict the onset of VAS and its progression could improve the management of this group of patients. In the current study, the levels of intercellular cell adhesion molecule 1 (ICAM-1), platelet/endothelial cell adhesion molecule 1 (PECAM-1), NSE (neuron-specific enolase), and the antibodies recognizing NR-2 subunit of NMDA receptor (NR-2-ab) were measured in the blood serum of BC survivor patients with vestibulo-atactic syndrome (VAS) and associated with the brain connectome data obtained via functional magnetic resonance imaging (fMRI) studies...
June 15, 2023: Pathophysiology: the Official Journal of the International Society for Pathophysiology